Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615837 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HTTALOX15MAPTNR2F2 | |
| SCHEMBL3608712 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2HTTMAPTNR2F2ALDH1A1 | |
| SCHEMBL3603064 | 0.85 | MAPT (0.32) | SMN1; SMN2HTTMAPTNR2F2 | |
| SCHEMBL3614211 | 0.80 | HPGD (0.33) | MAPTALDH1A1 | |
| SCHEMBL3615104 | 0.78 | ALDH1A1 (0.36) | SMN1; SMN2MAPTALDH1A1GAA | |
| SCHEMBL3613878 | 0.78 | ALDH1A1 (0.36) | SMN1; SMN2MAPTALDH1A1GAA | |
| SCHEMBL3613880 | 0.78 | ALDH1A1 (0.36) | SMN1; SMN2MAPTALDH1A1GAA | |
| SCHEMBL3602203 | 0.76 | NPC1 (0.31) | SMN1; SMN2 | |
| SCHEMBL3596945 | 0.75 | TDP1 (0.41) | ALDH1A1 | |
| SCHEMBL9674680 | 0.74 | ALDH1A1 (0.48) | SMN1; SMN2HTTALOX15MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | SMN1; SMN2 4515/4885HTT 4008/4885ALOX15 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.